Cargando…

Bamlanivimab/immunosuppressants: Headache/fatigue following off-label treatment and Coronavirus disease-2019: 18 case reports

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990634/ http://dx.doi.org/10.1007/s40278-022-12802-4

Ejemplares similares

Bamlanivimab: Transfusion-related acute lung injury following off label use: case report
Publicado: (2021)

Bamlanivimab: Gene mutation in COVID-19 infection and off label use: case report
Publicado: (2022)

Bamlanivimab: Diffuse C4d staining of peritubular capillaries following off-label use: case report
Publicado: (2022)

Bamlanivimab/casirivimab/imdevimab: Burning, eye pain and lack of efficacy following off-label use: 8 case reports
Publicado: (2022)

Hydroxychloroquine/immunosuppressants: Nosocomial coronavirus disease 2019 (COVID-19), leucopenia and prolonged persistence of COVID-19 following off-label use: case report
Publicado: (2020)

Hydrocortisone/methylprednisolone: Disuse syndrome following off-label use in coronavirus disease 2019: case report
Publicado: (2021)

Bamlanivimab: Guillain-Barre syndrome: case report
Publicado: (2021)

Bamlanivimab: New-onset seizures: case report
Publicado: (2022)

Monoclonal antibody infusion reaction with bamlanivimab and etesevimab in a 5-year-old male with coronavirus disease 2019: a case report
por: Pillai, Rajapillai L. I., et al.
Publicado: (2023)

Immunosuppressants: Coronavirus disease-2019: case report
Publicado: (2020)

Multiple drugs: Coronavirus disease-2019, lack of efficacy and off-label treatment: 21 case reports
Publicado: (2021)

Immunosuppressants: Coronavirus-2019 infection: 15 case reports
Publicado: (2020)

Immunosuppressants: Coronavirus disease 2019: 4 case reports
Publicado: (2020)

Corticosteroids/immunosuppressants: Coronavirus disease 2019: case report
Publicado: (2020)

Immunosuppressants: Coronavirus disease of 2019: 3 case reports
Publicado: (2022)

Real-World Experience of Bamlanivimab for Coronavirus Disease 2019 (COVID-19): A Case-Control Study
por: Kumar, Rebecca N, et al.
Publicado: (2021)

Ceftriaxone/doxycycline/immunosuppressants: Disseminated histoplasmosis following an off label use and lack of efficacy: case report
Publicado: (2022)

Deferasirox/hydroxychloroquine: Various toxicities and off-label use in coronavirus disease 2019: case report
Publicado: (2021)

Antivirals/immunosuppressants: COVID-19 infection and off label use: case report
Publicado: (2020)

Abatacept/immunosuppressants/ruxolitinib: Various toxicities following off-label use and lack of efficacy: 20 case reports
Publicado: (2022)

Corticosteroids/immunosuppressants/steroids: COVID-19 and lack of efficacy following off label use: 7 case reports
Publicado: (2022)

Immunosuppressants/lopinavir/ritonavir interaction: Relapse or persisting shedding of COVID-2019 , increased level of tacrolimus and off-label use: case report
Publicado: (2021)

Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019
por: O’Horo, John, et al.
Publicado: (2022)

Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019
por: Razonable, Raymund R., et al.
Publicado: (2022)

Multiple drugs: Acute pancreatitis, hypertriglyceridaemia and off-label use in coronavirus disease 2019: 2 case reports
Publicado: (2020)

Azithromycin: Acute generalised exanthematous pustulosis-like skin pustular eruption following off-label use in coronavirus disease 2019: case report
Publicado: (2021)

Hydroxychloroquine: Hepatotoxicity following off-label treatment: case report
Publicado: (2020)

Methylprednisolone: Strongyloidiasis following off-label treatment: case report
Publicado: (2022)

Multiple drugs: Off-label use, lack of efficacy and acquired immunosuppression syndrome: case report
Publicado: (2022)

Hydroxychloroquine: Thrombotic microangiopathy following off label treatment: case report
Publicado: (2021)

Favipiravir: Lack of efficacy following off-label treatment: case report
Publicado: (2021)

BAMLANIVIMAB-INDUCED GUILLAIN-BARRÉ SYNDROME
por: PALAGUACHI, GLADYS, et al.
Publicado: (2021)

Hydroxychloroquine/immunosuppressants: Delayed viral clearance, drug interaction and off label use: 3 case reports
Publicado: (2021)

Immunosuppressants/azithromycin: Prolonged COVID-19 infection, off label use and lack of efficacy: case report
Publicado: (2021)

500. A Real-World Cohort Study of Bamlanivimab Versus Bamlanivimab-Etesevimab for Non-severe COVID-19
por: Monday, Lea, et al.
Publicado: (2021)

Hydroxychloroquine: Stevens-Johnson syndrome following an off-label treatment: case report
Publicado: (2020)

Hydroxychloroquine: Premature ventricular contractions following an off label treatment: case report
Publicado: (2021)

Dexamethasone: Elizabethkingia meningoseptica sepsis following off-label treatment: case report
Publicado: (2021)

Atazanavir/ritonavir: QTc prolongation following off-label treatment: case report
Publicado: (2021)

Tocilizumab: Intrauterine fetal demise following off-label treatment: case report
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_49a633qh7i54hm836ahrkkvmkm